78269-85-9 Usage
Description
1-(2-(TRIMETHYLSILYL)ETHOXYCARBONYLOXY)&, also known as Teoc-OSu, is a silicon-based reagent derived from 2-trimethylsilylethyl carbonochloridite and N-hydroxysuccinimide. It is a white to off-white powder and is used as an acylating agent in the production of Teoc-amino acid derivatives.
Uses
Used in Pharmaceutical Industry:
Teoc-OSu is used as an acylating reagent for the synthesis of Teoc-amino acid derivatives, which are essential in the development of various pharmaceutical compounds. The reagent's ability to form stable derivatives with amino acids makes it a valuable tool in drug discovery and medicinal chemistry.
Used in Chemical Research:
In the field of chemical research, Teoc-OSu is utilized for the preparation of various organic compounds and materials. Its unique silicon-based structure allows for the exploration of new chemical reactions and the synthesis of novel molecules with potential applications in various industries.
Used in Material Science:
Teoc-OSu's silicon-based structure also makes it a candidate for use in material science, where it can be employed in the development of new materials with specific properties. These materials could have applications in electronics, coatings, or other advanced technologies.
Check Digit Verification of cas no
The CAS Registry Mumber 78269-85-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,2,6 and 9 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 78269-85:
(7*7)+(6*8)+(5*2)+(4*6)+(3*9)+(2*8)+(1*5)=179
179 % 10 = 9
So 78269-85-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H17NO5Si/c1-17(2,3)7-6-15-10(14)16-11-8(12)4-5-9(11)13/h4-7H2,1-3H3
78269-85-9Relevant articles and documents
MITOCHONDRIA-TARGETING PEPTIDES
-
Page/Page column 57, (2019/07/19)
Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.
NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS
-
, (2015/03/06)
Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of the a glycopeptide (Compound A, Compound B, Compound H or Compound C) or the monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; conversion of the amide group in amino acid-3 on these scaffolds to various acylamide, acylsulfonamide, acylsulfonylurea derivatives; aminomethylation with substituent containing sulfonamide or acylsulfonamide group on amino acid-7 through Mannich reaction; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Also provided are methods for the synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.
HIV PROTEASE INHIBITING COMPOUNDS
-
Page/Page column 115, (2010/02/12)
A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
